Elevated risks for undesirable events were also observed by using PD-1/PD-L1 inhibitors more than the usage of a placebo. Conclusion The usage of PD-1/PD-L1 inhibitors alone is connected with an improved safety profile in comparison to either the usage of chemotherapy or the usage of PD-1/PD-L1 inhibitors with various other anticancer regimens. Chemotherapy11Huang et?al. computed with the arbitrary impact (RE) model (PD-1/PD-L1 vs Chemotherapy). Subgroup evaluation was executed predicated on PD-1/PD-L1. Picture_1.tif (4.3M) GUID:?15B22237-9993-4826-9355-6183610A68D5 Supplementary Figure 2: Ro 08-2750 Funnel plots for group A (PD-1/PD-L1 vs Chemotherapy) (A) The chances ratio of treatment-related adverse events resulting in death calculated with the fixed effect (FE) model (PD-1/PD-L1 vs Chemotherapy). Subgroup evaluation was performed predicated on PD-1/PD-L1. (B) The chances proportion of treatment-related adverse occasions resulting in discontinuation calculated with the set impact (FE) model (PD-1/PD-L1 vs Chemotherapy). Subgroup evaluation was completed predicated on PD-1/PD-L1. (C) The chances proportion of all-grade treatment-related adverse occasions calculated with the set impact (FE) model (PD-1/PD-L1 vs Chemotherapy). Subgroup evaluation was executed predicated on PD-1/PD-L1. (D) The chances ratio of quality 3-5 treatment-related adverse occasions calculated by set impact (FE) model (PD-1/PD-L1 vs Chemotherapy). Subgroup evaluation was performed predicated on PD-1/PD-L1. Picture_2.tif (1.4M) GUID:?09763096-76E5-4C32-992D-A00BD3D9514F Supplementary Body 3: Funnel plots of treatment-related adverse events resulting in loss of life (A) The funnel story of treatment-related adverse events resulting in death calculated with the set effect (FE) super model tiffany livingston in Group A (PD-1/PD-L1 vs Chemotherapy). Subgroup evaluation was performed predicated on tumor types. (B) The funnel story of treatment-related adverse occasions leading to loss of life calculated with the set impact (FE) model in Group B (PD-1/PD-L1+Chemotherapy vs Chemotherapy). Subgroup evaluation was performed predicated on tumor types. (C) The funnel story of treatment-related adverse occasions leading to loss of life calculated with the set impact (FE) model in Group C (PD-1/PD-L1 vs Placebo). (D) The funnel story of treatment-related adverse occasions leading to loss of life calculated with the set impact (FE) model in Group D (PD-1 vs PD-1+CTLA-4). Subgroup evaluation was performed predicated on tumor types. (E) The funnel story of treatment-related adverse occasions leading to loss of life calculated with the set impact (FE) model in Group E (PD-1+CTLA-4 vs CTLA-4). (F) The funnel story of treatment-related adverse occasions leading to loss of life calculated with the set impact (FE) model in Group F (PD-1 vs CTLA-4). (G) The funnel story of treatment-related adverse occasions leading to loss of life calculated with the fixed effect (FE) model in Group G (PD-1/PD-L1 vs PD-1/PD-L1+Chemotherapy). Image_3.tif (2.4M) GUID:?DC59D554-BBB4-4DA0-B3BC-C11E266F2C11 Supplementary Figure 4: Funnel plots of the risk of treatment-related adverse events leading to discontinuation (A) The funnel plot of treatment-related adverse events leading to discontinuation calculated by the fixed effect (FE) model in Group A (PD-1/PD-L1 vs Chemotherapy). Subgroup analysis was performed based on tumor types, PD-1/PD-L1 and treatment regimens. (B) The funnel plot of treatment-related adverse events leading to death calculated by the fixed effect (FE) model in Group B (PD-1/PD-L1+Chemotherapy vs Chemotherapy). Subgroup analysis was performed based on PD-1/PD-L1. (C) The funnel plot of treatment-related adverse events leading to discontinuation calculated by the fixed effect (FE) model in Group C (PD-1/PD-L1 vs Placebo). Subgroup analysis was performed based on tumor types. (D) The funnel plot of treatment-related adverse events leading to discontinuation calculated by the fixed effect (FE) model in Group D (PD-1 vs PD-1+CTLA-4). Subgroup analysis was performed based on tumor types. (E) The funnel plot of treatment-related adverse events leading to discontinuation calculated by the fixed effect (FE) model in Group E (PD-1+CTLA-4 vs CTLA-4). (F) The funnel plot of treatment-related adverse events leading to discontinuation calculated by the fixed effect (FE) model in Group F (PD-1 vs CTLA-4). Image_4.tif (2.0M) GUID:?C4604C64-794E-4B16-9D7D-A40013F23115 Supplementary Figure 5: Funnel plots of all-grade treatment-related adverse events (A) The funnel plot of all-grade treatment-related adverse events calculated by the fixed effect (FE) model in Group A (PD-1/PD-L1 vs Chemotherapy) Subgroup analysis was performed based on tumor types, PD-1/PD-L1 and treatment regimens. (B) The funnel plot of all-grade treatment-related adverse events calculated by the fixed effect (FE) model in Group B (PD-1/PD-L1+Chemotherapy vs Chemotherapy). Subgroup analysis was performed based on PD-1/PD-L1 and tumor types. (C) The funnel plot for all grade treatment-related adverse events calculated by the fixed effect (FE) model in Group C (PD-1/PD-L1 vs Placebo). Subgroup analysis was performed based on PD-1/PD-L1 and tumor types. (D) The funnel plot of all-grade treatment-related adverse events calculated by the fixed effect (FE) model in Group D (PD-1 vs PD-1+CTLA-4). Subgroup analysis was performed based on tumor types. (E) The funnel plot of all-grade treatment-related adverse events calculated by the fixed effect (FE) model in Group E (PD-1+CTLA-4 vs CTLA-4). (F) The funnel plot of all-grade treatment-related adverse events calculated by the fixed effect (FE) model.Subgroup analysis was performed based on tumor types. based on PD-1/PD-L1. (C) The odds ratio of all-grade treatment-related adverse events calculated by the fixed effect (FE) model (PD-1/PD-L1 vs Chemotherapy). Subgroup analysis was conducted based on PD-1/PD-L1. (D) The odds ratio of grade 3-5 treatment-related adverse events calculated by fixed effect (FE) model (PD-1/PD-L1 vs Chemotherapy). Subgroup analysis was performed based on PD-1/PD-L1. Image_2.tif (1.4M) GUID:?09763096-76E5-4C32-992D-A00BD3D9514F Supplementary Figure 3: Funnel plots of treatment-related adverse events leading to death (A) The funnel plot of treatment-related adverse events leading to death calculated by the fixed effect (FE) model in Group A (PD-1/PD-L1 vs Chemotherapy). Subgroup analysis was performed based on tumor types. (B) The funnel plot of treatment-related adverse events leading to death calculated by the fixed effect (FE) model in Group B (PD-1/PD-L1+Chemotherapy vs Chemotherapy). Subgroup analysis was performed based on tumor types. (C) The funnel plot of treatment-related adverse events leading to death calculated by the fixed effect (FE) model in Group C (PD-1/PD-L1 vs Placebo). (D) The funnel plot of treatment-related adverse events leading to death calculated by the fixed effect (FE) model in Group D (PD-1 vs PD-1+CTLA-4). Subgroup analysis was performed based on tumor types. (E) The funnel plot of treatment-related adverse events leading to death calculated by the fixed effect (FE) model in Group E (PD-1+CTLA-4 vs CTLA-4). (F) The funnel plot of treatment-related adverse events leading to death calculated by the fixed effect (FE) model in Group F (PD-1 vs CTLA-4). (G) The funnel plot of treatment-related adverse events leading to death calculated by the fixed effect (FE) model in Group G (PD-1/PD-L1 vs PD-1/PD-L1+Chemotherapy). Image_3.tif (2.4M) GUID:?DC59D554-BBB4-4DA0-B3BC-C11E266F2C11 Supplementary Figure 4: Funnel plots of the risk of treatment-related adverse events leading to discontinuation (A) The funnel plot of treatment-related adverse events leading to discontinuation calculated by the fixed effect (FE) model in Group A (PD-1/PD-L1 vs Chemotherapy). Subgroup analysis was performed based on tumor types, PD-1/PD-L1 and treatment regimens. (B) The funnel plot of treatment-related adverse events leading to death calculated by the fixed effect (FE) model in Group FIGF B (PD-1/PD-L1+Chemotherapy vs Chemotherapy). Subgroup analysis was performed based on PD-1/PD-L1. (C) The funnel plot of treatment-related adverse events leading to discontinuation calculated by the fixed effect (FE) model in Group C (PD-1/PD-L1 vs Placebo). Subgroup analysis was performed based on tumor types. (D) The funnel plot of treatment-related adverse events leading to discontinuation calculated by the fixed effect (FE) model in Group D (PD-1 vs PD-1+CTLA-4). Subgroup analysis was performed based on tumor types. (E) The funnel plot of treatment-related adverse events leading to discontinuation calculated from the fixed effect (FE) model in Group E (PD-1+CTLA-4 vs CTLA-4). (F) The funnel storyline of treatment-related adverse events leading to discontinuation calculated from the fixed effect (FE) model in Group F (PD-1 vs CTLA-4). Image_4.tif (2.0M) GUID:?C4604C64-794E-4B16-9D7D-A40013F23115 Supplementary Figure 5: Funnel plots of all-grade treatment-related adverse events (A) The funnel plot of all-grade treatment-related adverse events calculated from the fixed effect (FE) model in Group A (PD-1/PD-L1 vs Chemotherapy) Subgroup analysis was performed based on tumor types, PD-1/PD-L1 and treatment regimens. (B) The funnel storyline of all-grade treatment-related adverse events calculated from the fixed effect (FE) model in Group B (PD-1/PD-L1+Chemotherapy vs Chemotherapy). Subgroup analysis was performed based on PD-1/PD-L1 and tumor types. (C) The funnel storyline for all grade treatment-related adverse events calculated from the fixed effect (FE) model in Group C (PD-1/PD-L1 vs Placebo). Subgroup analysis was performed based on PD-1/PD-L1 and tumor types. (D) The funnel storyline of all-grade Ro 08-2750 treatment-related adverse events calculated from the fixed effect (FE) model in Group D (PD-1 vs PD-1+CTLA-4). Subgroup Ro 08-2750 analysis was performed based on tumor types. (E) The funnel storyline of all-grade treatment-related adverse events calculated from the fixed effect (FE) model in Group E (PD-1+CTLA-4 vs CTLA-4). (F) The funnel storyline of all-grade treatment-related adverse events calculated from the fixed effect (FE) model in Group F (PD-1 vs CTLA-4). Image_5.tif (2.3M) GUID:?D5643454-FB71-4D07-A2A0-3D0AAAAD64E6 Supplementary Figure 6:.(B) The odds percentage of treatment-related adverse events leading to discontinuation calculated from the random effect (RE) magic size (PD-1/PD-L1 vs Chemotherapy). on PD-1/PD-L1. (B) The odds percentage of treatment-related adverse events leading to discontinuation calculated from the fixed effect (FE) model (PD-1/PD-L1 vs Chemotherapy). Subgroup analysis was carried out based on PD-1/PD-L1. (C) The odds percentage of all-grade treatment-related adverse events calculated from the fixed effect (FE) model (PD-1/PD-L1 vs Chemotherapy). Subgroup analysis was carried out based on PD-1/PD-L1. (D) The odds ratio of grade 3-5 treatment-related adverse events calculated by fixed effect (FE) model (PD-1/PD-L1 vs Chemotherapy). Subgroup analysis was performed based on PD-1/PD-L1. Image_2.tif (1.4M) GUID:?09763096-76E5-4C32-992D-A00BD3D9514F Supplementary Number 3: Funnel plots of treatment-related adverse events leading to death (A) The funnel storyline of treatment-related adverse events leading to death calculated from the fixed effect (FE) magic size in Group A (PD-1/PD-L1 vs Chemotherapy). Subgroup analysis was performed based on tumor types. (B) The funnel storyline of treatment-related adverse events leading to death calculated from the fixed effect (FE) model in Group B (PD-1/PD-L1+Chemotherapy vs Chemotherapy). Subgroup analysis was performed based on tumor types. (C) The funnel storyline of treatment-related adverse events leading to death calculated from the fixed effect (FE) model in Group C (PD-1/PD-L1 vs Placebo). (D) The funnel storyline of treatment-related adverse events leading to death calculated from the fixed effect (FE) model in Group D (PD-1 vs PD-1+CTLA-4). Subgroup analysis was performed based on tumor types. (E) The funnel storyline of treatment-related adverse events leading to death calculated from the fixed effect (FE) model in Group E (PD-1+CTLA-4 vs CTLA-4). (F) The funnel storyline of treatment-related adverse events leading to death calculated from the fixed effect (FE) model in Group F (PD-1 vs CTLA-4). (G) The funnel storyline of treatment-related adverse events leading to death calculated from the fixed effect (FE) model in Group G (PD-1/PD-L1 vs PD-1/PD-L1+Chemotherapy). Image_3.tif (2.4M) GUID:?DC59D554-BBB4-4DA0-B3BC-C11E266F2C11 Supplementary Number 4: Funnel plots of the risk of treatment-related adverse events leading to discontinuation (A) The funnel storyline of treatment-related adverse events leading to discontinuation calculated from the fixed effect (FE) magic size in Group A (PD-1/PD-L1 vs Chemotherapy). Subgroup analysis was performed based on tumor types, PD-1/PD-L1 and treatment regimens. (B) The funnel storyline of treatment-related adverse events leading to death calculated from the fixed effect (FE) model in Group B (PD-1/PD-L1+Chemotherapy vs Chemotherapy). Subgroup analysis was performed based on PD-1/PD-L1. (C) The funnel storyline of treatment-related adverse events leading to discontinuation calculated from the fixed effect (FE) model in Group C (PD-1/PD-L1 vs Placebo). Subgroup analysis was performed based on tumor types. (D) The funnel storyline of treatment-related adverse events leading to discontinuation calculated from the fixed effect (FE) model in Group D (PD-1 vs PD-1+CTLA-4). Subgroup analysis was performed based on tumor types. (E) The funnel storyline of treatment-related adverse events leading to discontinuation calculated from the fixed effect (FE) model in Group E (PD-1+CTLA-4 vs CTLA-4). (F) The funnel storyline of treatment-related adverse events leading to discontinuation calculated from the fixed effect (FE) model in Group F (PD-1 vs CTLA-4). Image_4.tif (2.0M) GUID:?C4604C64-794E-4B16-9D7D-A40013F23115 Supplementary Figure 5: Funnel plots of all-grade treatment-related adverse events (A) The funnel plot of all-grade treatment-related adverse events calculated from the fixed effect (FE) model in Group A (PD-1/PD-L1 vs Chemotherapy) Subgroup analysis was performed based on tumor types, PD-1/PD-L1 and treatment regimens. (B) The funnel storyline of all-grade treatment-related adverse events calculated from the fixed effect (FE) model in Group B (PD-1/PD-L1+Chemotherapy vs Chemotherapy). Subgroup analysis was performed based on PD-1/PD-L1 and tumor types. (C) The funnel storyline for all grade treatment-related adverse events calculated from the fixed effect (FE) model in Group C (PD-1/PD-L1 vs Placebo). Subgroup analysis was performed based on PD-1/PD-L1 and tumor types. (D) The funnel storyline of all-grade treatment-related adverse events calculated by the fixed effect (FE) model in Group D (PD-1 vs PD-1+CTLA-4). Subgroup analysis was performed based on tumor types. (E) The funnel plot of all-grade treatment-related adverse events calculated by the fixed effect (FE) model in Group E (PD-1+CTLA-4 vs CTLA-4). (F) The funnel plot of all-grade treatment-related adverse events calculated by the fixed effect (FE) model in Group F (PD-1 vs CTLA-4). Image_5.tif (2.3M) GUID:?D5643454-FB71-4D07-A2A0-3D0AAAAD64E6 Supplementary Figure 6: Funnel plots of grade 3-5 treatment-related adverse events. (A) The funnel plot of grade 3-5 treatment-related adverse events calculated by the fixed effect (FE) model in Group A (PD-1/PD-L1 vs Chemotherapy). Subgroup analysis was performed based on.Subgroup analysis was performed based on PD-1/PD-L1 and tumor types. conducted based on PD-1/PD-L1. Image_1.tif (4.3M) GUID:?15B22237-9993-4826-9355-6183610A68D5 Supplementary Figure 2: Funnel plots for group A (PD-1/PD-L1 vs Chemotherapy) (A) The odds ratio of treatment-related adverse events leading to death calculated by the fixed effect (FE) model (PD-1/PD-L1 vs Chemotherapy). Subgroup analysis was performed based on PD-1/PD-L1. (B) The odds ratio of treatment-related adverse events leading to discontinuation calculated by the fixed effect (FE) model (PD-1/PD-L1 vs Chemotherapy). Subgroup analysis was carried out based on PD-1/PD-L1. (C) The odds ratio of all-grade treatment-related adverse events calculated by the fixed effect (FE) model (PD-1/PD-L1 vs Chemotherapy). Subgroup analysis was conducted based on PD-1/PD-L1. (D) The odds ratio of grade 3-5 treatment-related adverse events calculated by fixed effect (FE) model (PD-1/PD-L1 vs Chemotherapy). Subgroup analysis was performed based on PD-1/PD-L1. Image_2.tif (1.4M) GUID:?09763096-76E5-4C32-992D-A00BD3D9514F Supplementary Physique 3: Funnel plots of treatment-related adverse events leading to death (A) The funnel plot of treatment-related adverse events leading to death calculated by the fixed effect (FE) model in Group A (PD-1/PD-L1 vs Chemotherapy). Subgroup analysis was performed based on tumor types. (B) The funnel plot of treatment-related adverse events leading to death calculated by the fixed effect (FE) model in Group B (PD-1/PD-L1+Chemotherapy vs Chemotherapy). Subgroup analysis was performed based on tumor types. (C) The funnel plot of treatment-related adverse events leading to death calculated by the fixed effect (FE) model in Group C (PD-1/PD-L1 vs Placebo). (D) The funnel plot of treatment-related adverse events leading to death calculated by the fixed effect (FE) model in Group D (PD-1 vs PD-1+CTLA-4). Subgroup analysis was performed based on tumor types. (E) The funnel plot of treatment-related adverse events leading to death calculated by the fixed effect (FE) model in Group E (PD-1+CTLA-4 vs CTLA-4). (F) The funnel plot of treatment-related adverse events leading to death calculated by the fixed effect (FE) model in Group F (PD-1 vs CTLA-4). (G) The funnel plot of treatment-related adverse events leading to death calculated by the fixed effect (FE) model in Group G (PD-1/PD-L1 vs PD-1/PD-L1+Chemotherapy). Image_3.tif (2.4M) GUID:?DC59D554-BBB4-4DA0-B3BC-C11E266F2C11 Supplementary Physique 4: Funnel plots of the risk of treatment-related adverse events leading to discontinuation (A) The funnel plot of treatment-related adverse events leading to discontinuation calculated by the fixed effect (FE) model in Group A (PD-1/PD-L1 vs Chemotherapy). Subgroup analysis was performed based on tumor types, PD-1/PD-L1 and treatment regimens. (B) The funnel plot of treatment-related adverse events leading to death calculated by the fixed effect (FE) model in Group B (PD-1/PD-L1+Chemotherapy vs Chemotherapy). Subgroup analysis was performed based on PD-1/PD-L1. (C) The funnel plot of treatment-related adverse events leading to discontinuation calculated by the fixed effect (FE) model in Group C (PD-1/PD-L1 vs Placebo). Subgroup analysis was performed based on tumor types. (D) The funnel plot of treatment-related adverse events leading to discontinuation calculated by the fixed effect (FE) model in Group D (PD-1 vs PD-1+CTLA-4). Subgroup analysis was performed based on tumor types. (E) The funnel plot of treatment-related adverse events leading to discontinuation calculated by the fixed effect (FE) model in Group E (PD-1+CTLA-4 vs CTLA-4). (F) The funnel plot of treatment-related adverse events leading to discontinuation calculated by the fixed effect (FE) model in Group F (PD-1 vs CTLA-4). Image_4.tif (2.0M) GUID:?C4604C64-794E-4B16-9D7D-A40013F23115 Supplementary Figure 5: Funnel plots of all-grade treatment-related adverse events (A) The funnel plot of all-grade treatment-related adverse events calculated by the fixed effect (FE) model in Group A (PD-1/PD-L1 vs Chemotherapy) Subgroup analysis was performed based on tumor types, PD-1/PD-L1 and treatment regimens. (B) The funnel plot of all-grade treatment-related adverse events calculated by the fixed effect (FE) model in Group B (PD-1/PD-L1+Chemotherapy vs Chemotherapy). Subgroup analysis was performed based on PD-1/PD-L1 and tumor types. (C) The funnel plot for all grade treatment-related adverse events calculated by the fixed effect (FE).